sponsored
PatientsVille.com Logo

PatientsVille

Chills Medical Research Studies

Up-to-date List of Chills Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Chills Medical Research Studies

Rank Status Study
1 Recruiting Mild Versus Moderate Therapeutic Hypothermia in Out-of-hospital Cardiac Arrest Patients
Condition: Cardiac Arrest
Intervention: Other: Therapeutic Hypothermia
Outcome Measures: Number of participants with death or poor neurologic outcome at 6 months;   Number of mortality;   Number of participants with stroke;   Number of participants with bleeding;   Length of stay in the unit;   Length of stay in the hospital;   Number of participants with cardiogenic shock;   Number of participants with repeat circulatory arrest requiring cardiopulmonary resuscitation (CPR);   Number of participants with seizures;   Number of participants with renal failure requiring renal replacement therapy;   Number of participants with ventilator associated pneumonia;   Number of participants with stent thrombosis;   Number of participants discharged home
2 Unknown  A Preliminary Study on Effect of Omega-3 on Human Sperm
Condition: Oligospermia
Intervention: Behavioral: commercially available omega-3 fatty acids supplementation
Outcome Measures: sperm count;   sperm Lipid phase transition determination
3 Recruiting A Post-marketing Study to Monitor the Safety of a MF59-adjuvanted Influenza Vaccine Administered in Korean Subjects Aged 65 Years or Older
Condition: Influenza (Seasonal)
Interventions: Biological: Novartis MF59-adjuvanted influenza subunit vaccine;   Biological: Sandoz Korea MF59-adjuvanted influenza subunit vaccine
Outcome Measures: Occurrence of solicited local (tenderness, erythema, induration, swelling and pain at the injection site) and systemic reactions (CHILLS, myalgia, arthralgia, headache, sweating, fatigue and fever);   Occurrence of unsolicited adverse events;   Occurrence of serious adverse events
4 Recruiting Small-dose Dexmedetomidine Effects on Recovery Profiles of Supratentorial Tumors Patients From General Anesthesia
Conditions: Brain Neoplasms;   Surgery
Interventions: Drug: dexmedetomidine;   Drug: normal saline
Outcome Measures: Hemodynamic impacts;   Time of recovery from anesthesia;   Cough assessment at tracheal extubation;   Degree of sedation;   Sedative effectiveness;   Test patient's blood pressure during maintenance of anesthesia;   Monitor Patient's heart beat during maintenance of anesthesia;   Test patient's blood pressure during anesthesia recovery period;   Monitor Patient's heart beat during anesthesia recovery period;   Observe CHILLS reaction;   To measure palinesthesia
5 Recruiting Open Label Pharmacokinetic-Pharmacogenetic Study on Polymorphisms in the Organic Cation Transporter OCT1
Conditions: Drug Metabolism;   Membrane Transport
Interventions: Drug: Drug application Amitriptyline;   Drug: Drug application Desvenlafaxine;   Drug: Drug application Sumatriptan;   Drug: Drug application Proguanil
Outcome Measures: Area under the plasma concentration-time curve (AUC) of the investigational drugs;   Total clearance, Cmax, Tmax, Mean AbsorptionTime, Alpha and Beta half-lives, Mean Residence Time (MRT) and Volume of distribution of the investigated drugs and their metabolites;   Dry mouth, fatigue, nausea, headache, vertigo, tinnitus, CHILLS, anxiety and difficulties to read on Visual Analog Scales.;   Sedation on Stanford sedation scale;   Pupil diameter, latency, diameter at maximal constriction, amplitude and time for 33% recovery of initial pupil diameter measured by pupillometrie;   Genetic variants in OCT1, CYP2C19, CYP2D6 and MAO A
6 Recruiting Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin
Condition: Hepatitis C
Interventions: Biological: Pegylated Interferon Lambda;   Drug: Ribasphere;   Drug: Daclatasvir
Outcome Measures: Antiviral activity, as determined by the proportion of non-cirrhotic HCV GT-1b subjects with 12-week sustained virologic response (SVR12), defined as HCV RNA < LLOQ target detected or not detected;   Proportion of non-cirrhotic HCV GT-1b subjects with eRVR, defined as HCV RNA < LLOQ target not detected;   Proportion of non-cirrhotic HCV GT-1b subjects with treatment-emergent cytopenic abnormalities (anemia as defined by Hb < 10 g/dL, and/or neutropenia as defined by ANC < 750 mm3, and/or thrombocytopenia as defined by platelets < 50,000 mm3) on treatment;   Proportion of non-cirrhotic HCV GT-1b subjects with on-treatment (maximum of 12 weeks) interferon-associated flu-like symptoms (pyrexia or CHILLS or pain);   Proportion of non-cirrhotic HCV GT-1b subjects with on-treatment (maximum of 12 weeks) interferon-associated musculoskeletal symptoms (arthralgia or myalgia or back pain);   Proportion of non-cirrhotic HCV GT-1b subjects with SVR24, defined as HCV RNA < LLOQ target detected or not detected;   Frequency of deaths among non-cirrhotic HCV GT-1b subjects through the end of follow-up (maximum of 60 weeks);   Frequency of Serious adverse events (SAEs) among non-cirrhotic HCV GT-1b subjects through the end of follow-up (maximum of 60 weeks);   Frequency of drug related Adverse events (AEs) among non-cirrhotic HCV GT-1b subjects through the end of treatment (maximum of 12 weeks);   Frequency of dose reductions and discontinuations due to AEs among non-cirrhotic HCV GT-1b subjects through the end of treatment (maximum of 12 weeks);   Frequency of treatment emergent laboratory abnormalities among non-cirrhotic HCV GT-1b subjects through the end of treatment (maximum of 12 weeks);   Proportion of non-cirrhotic HCV GT-1b subjects with interferon-associated constitutional symptoms (fatigue or asthenia) through the end of treatment (maximum of 12 weeks);   Proportion of non-cirrhotic HCV GT-1b subjects with interferon-associated neurologic symptoms (headache or dizziness) through the end of treatment (maximum of 12 weeks);   Proportion of non-cirrhotic HCV GT-1b subjects with psychiatric symptoms (depression or irritability or insomnia) through the end of treatment (maximum of 12 weeks)
7 Recruiting Effect of Filarial Infection on Immune Responses in Latent Tuberculosis
Conditions: Tuberculosis;   Filariasis
Intervention:
Outcome Measures: To compare the immune responses to mycobacterial antigens, including PPD and Mycobacterium tuberculosis culture filtrate protein, in individuals who are LTBI+ Fil- versus those who are LTBI+ Fil+.;   To compare immune responses to mycobacterial antigens in LTBI+Fil+ co-infected individuals, before and after treatment for filarialinfection.
8 Recruiting Efficacy and Safety Study of Pegylated Interferon Lambda-1a With Ribavirin and Daclatasvir, to Treat naïve Subjects With Chronic HCV Genotypes 1, 2, 3, and 4 Who Are Co-infected With HIV
Condition: Chronic Hepatitis C Infection
Interventions: Biological: Pegylated Interferon Lambda-1a;   Drug: Daclatasvir (DCV);   Drug: Ribasphere (RBV)
Outcome Measures: Antiviral activity, as determined by the proportion of subjects with SVR12, defined as HCV RNA <LLOQ (25 IU/mL), target detected or target not detected, for each treatment arm;   Proportion of subjects with Rapid virologic response (RVR) and Extended Rapid Virologic Response (eRVR), where RVR is defined as <LLOQ target not detected at week 4 and eRVR defined as <LLOQ target not detected at Weeks 4 and 12;   Proportion of subjects in each group/duration who achieve HCV RNA <LLOQ target detected or not detected, at end of therapy (SVR24);   Proportion of subjects with treatment emergent cytopenic abnormalities (anemia as defined by Hb <10 g/dL, and/or neutropenia as defined by ANC <750 mm3 and/or thrombocytopenia as defined by platelets <50,000 mm3) during the treatment period;   Proportion of subjects with the following on treatment IFN-associated symptoms: flu-like symptoms (as defined by pyrexia or CHILLS or pain) and musculoskeletal symptoms (as defined by arthralgia or myalgia or back pain);   Frequency of deaths, serious adverse events (SAEs), discontinuations due to Adverse Events (AEs), dose reductions, and severity Grade 3/4 laboratory abnormalities;   Absolute and percent change from baseline in the CD4 cell count, lymphocyte cell count, and platelet count
9 Recruiting Pioglitazone to Treat Opioid Withdrawal Symptoms
Condition: Opioid-Related Disorders
Interventions: Drug: Pioglitazone;   Drug: Placebo
Outcome Measures: Treatment response, defined as opioid abstinence without severe withdrawal symptoms during the last week of the taper (week 6) and duration in treatment (retention);   Overall proportions of opioid-negative urines, proportions of participants needing adjunct medications status at follow-up
10 Recruiting Treatment and Natural History Study of Lymphomatoid Granulomatosis
Condition: Lymphomatoid Granulomatosis
Intervention:
Outcome Measure:
11 Recruiting Pre-warmed Intravenous Fluids and Monitored Anesthesia Care
Condition: Hypothermia
Interventions: Other: Pre-warmed fluids;   Other: Room temperature fluids
Outcome Measures: Tympanic membrane temperature;   Postoperative chilling and shivering
12 Recruiting Hyperinvasive Approach in Cardiac Arrest
Condition: Out-of Hospital Cardiac Arrest
Interventions: Device: Prehospital mechanical compression device, intraarrest cooling and in hospital ECLS (LUCAS, Rhinochill, PLS ECMO);   Other: Standard care
Outcome Measures: Composite endpoint of survival with good neurological outcome (CPC 1-2).;   Neurological recovery;   Cardiac recovery
13 Recruiting A Migration and Bone Density Study Comparing Hi-Fatigue Bone Cement and Palacos Bone Cement
Condition: Hip Arthritis
Interventions: Device: Hi-Fatigue Bone Cement;   Device: Palacos Bone Cement
Outcome Measure: Femoral component migration (roentgen stereo photogrammetric analysis - RSA)
14 Recruiting Inhaled Nitric Oxide and Inhaled Prostacyclin After Cardiac Surgery for Heart Transplant or LVAD Placement
Condition: Heart Failure
Interventions: Drug: Nitric Oxide;   Drug: Prostacyclin
Outcome Measures: Pulmonary Hypertension;   Right heart dysfunction

These studies may lead to new treatments and are adding insight into Chills etiology and treatment.

A major focus of Chills research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Chills